• Recruiting

NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma

Updated: Oct 19

CELMoD - CC-92480 - Mezigdomide - MEZI


NCT05372354: Phase 1/2: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

CELMoD - CC-92480 - Mezigdomide - MEZI

NCT05372354: Phase 1/2: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma


The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).


Sponsor

Bristol-Myers Squibb


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT05372354

Official Title: An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma

First Posted : May 12, 2022

Click here for details on ClinicalTrials.gov

 

cereblon E3 ubiquitin ligase modulating agent CC-92480

CC-92480


Mezigdomide (Code C146660)

CC 92480

CC-92480

CELMoD CC-92480

Cereblon E3 Ligase Modulation Drug CC-92480

Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480

Cereblon Modulator CC-92480

Mezigdomide

MEZIGDOMIDE

 

Drug: CC-92480

Drug: Tazemetostat

Drug: BMS-986158

Drug: Trametinib

Drug: Dexamethasone

 

Locations

United States, Alabama

United States, New York

Canada, Ontario

Europe

Norway

Spain

United Kingdom

 

RELATED POSTS

NCT05552976: Phase 3: (SUCCESSOR-2) CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM

Click here for details


NCT05519085: Phase 3: (SUCCESSOR-1) CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM

Click here for details


NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

Click here for details


NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma

Click here for details

MEZIGDOMIDE

Posts Archive